{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}, {"key": "in-the-territory", "type": "clause", "offset": [111, 127]}, {"key": "active-substance", "type": "definition", "offset": [143, 159]}, {"key": "for-api", "type": "clause", "offset": [184, 191]}, {"key": "by-a-party", "type": "clause", "offset": [221, 231]}, {"key": "regulatory-authorities", "type": "clause", "offset": [235, 257]}], "size": 47, "samples": [{"hash": "iUNmoR2wqWA", "uri": "/contracts/iUNmoR2wqWA#dmf", "label": "Collaboration and License Agreement (Ambrx Biopharma Inc.)", "score": 32.4031486511, "published": true}, {"hash": "dCQF4sNilTb", "uri": "/contracts/dCQF4sNilTb#dmf", "label": "Collaboration and License Agreement (Ambrx Biopharma Inc.)", "score": 32.4031486511, "published": true}, {"hash": "gYVTh1S5WGx", "uri": "/contracts/gYVTh1S5WGx#dmf", "label": "Collaboration and License Agreement (Ambrx Biopharma Inc.)", "score": 32.2005462646, "published": true}], "snippet": "means a drug master file and all equivalents, and related proprietary dossiers, in any country or jurisdiction in the Territory (including any active substance master file in the EMA) for API submitted or to be submitted by a Party to Regulatory Authorities.", "hash": "bf9651d8bf10362240c05c886135f991", "id": 1}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [10, 26]}, {"key": "the-fda", "type": "clause", "offset": [38, 45]}, {"key": "other-countries", "type": "clause", "offset": [76, 91]}], "size": 37, "samples": [{"hash": "25tl54bJL63", "uri": "/contracts/25tl54bJL63#dmf", "label": "Master Collaboration and License Agreement", "score": 32.8346099854, "published": true}, {"hash": "c6HFj3QbN4c", "uri": "/contracts/c6HFj3QbN4c#dmf", "label": "Services and Collaboration Agreement (Moderna, Inc.)", "score": 29.8542098999, "published": true}, {"hash": "5RZPiYInoI7", "uri": "/contracts/5RZPiYInoI7#dmf", "label": "Master Collaboration and License Agreement (Moderna, Inc.)", "score": 29.8542098999, "published": true}], "snippet": "means any drug master file filed with the FDA, and any equivalent filing in other countries or regulatory jurisdictions.", "hash": "626ef050514478da4c28d0eb76eb9456", "id": 2}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}, {"key": "the-fda", "type": "clause", "offset": [111, 118]}, {"key": "governmental-authority", "type": "clause", "offset": [128, 150]}, {"key": "regulatory-authority", "type": "definition", "offset": [154, 174]}, {"key": "to-provide", "type": "definition", "offset": [192, 202]}, {"key": "detailed-information", "type": "definition", "offset": [216, 236]}], "size": 35, "samples": [{"hash": "4rXMuZ1nWO5", "uri": "/contracts/4rXMuZ1nWO5#dmf", "label": "License and Development Agreement (Cerecor Inc.)", "score": 29.3559207916, "published": true}, {"hash": "4OIrP1kulad", "uri": "/contracts/4OIrP1kulad#dmf", "label": "License and Development Agreement (Cerecor Inc.)", "score": 29.3559207916, "published": true}, {"hash": "bew7NpLCKwj", "uri": "/contracts/bew7NpLCKwj#dmf", "label": "License and Development Agreement (Avadel Pharmaceuticals PLC)", "score": 29.3258037567, "published": true}], "snippet": "means a drug master file, as provided for in 21 CFR \u00a7 314.420 or similar submission to or file maintained with the FDA or other Governmental Authority or Regulatory Authority that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.", "hash": "a81efcf0da68ede354fbfd119b3265fa", "id": 3}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [48, 72]}, {"key": "from-time-to-time", "type": "clause", "offset": [98, 115]}, {"key": "during-the-term", "type": "clause", "offset": [116, 131]}, {"key": "by-cydex", "type": "clause", "offset": [133, 141]}, {"key": "the-fda", "type": "clause", "offset": [147, 154]}], "size": 30, "samples": [{"hash": "9Bb8FvoZQxI", "uri": "/contracts/9Bb8FvoZQxI#dmf", "label": "Commercial License Agreement (Sage Therapeutics, Inc.)", "score": 34.5961685181, "published": true}, {"hash": "fCfwOLzGGtc", "uri": "/contracts/fCfwOLzGGtc#dmf", "label": "Supply Agreement (Ligand Pharmaceuticals Inc)", "score": 27.835729599, "published": true}, {"hash": "bUJ22ak8BSx", "uri": "/contracts/bUJ22ak8BSx#dmf", "label": "Licensing Agreement", "score": 27.0369606018, "published": true}], "snippet": "means a Drug Master File for Captisol, as filed as of the Effective Date, or as hereafter updated from time to time during the Term, by CyDex with the FDA.", "hash": "c6f64fa213e055977cfefbea7966db56", "id": 4}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}], "size": 25, "samples": [{"hash": "fKVNzMtEf7q", "uri": "/contracts/fKVNzMtEf7q#dmf", "label": "Manufacturing and Supply Agreement (Lantheus Medical Imaging, Inc.)", "score": 25.188911438, "published": true}, {"hash": "cZYiybqILzj", "uri": "/contracts/cZYiybqILzj#dmf", "label": "Manufacturing and Supply Agreement (Lantheus Medical Imaging, Inc.)", "score": 23.7378501892, "published": true}, {"hash": "at9ykBGn4wS", "uri": "/contracts/at9ykBGn4wS#dmf", "label": "Manufacturing and Supply Agreement (Lantheus Medical Imaging, Inc.)", "score": 23.6173858643, "published": true}], "snippet": "means a Drug Master File as described in 21 CFR 14.420.", "hash": "37a8e41d2defedfaf49440d6483486ca", "id": 5}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}, {"key": "regulatory-authority", "type": "definition", "offset": [43, 63]}, {"key": "within-the-territory", "type": "clause", "offset": [79, 99]}], "size": 25, "samples": [{"hash": "8CWIKsQn2SX", "uri": "/contracts/8CWIKsQn2SX#dmf", "label": "Exclusive License Agreement (Keros Therapeutics, Inc.)", "score": 36.1540031433, "published": true}, {"hash": "55q6KS84pGq", "uri": "/contracts/55q6KS84pGq#dmf", "label": "License Agreement (Kazia Therapeutics LTD)", "score": 32.7645454407, "published": true}, {"hash": "kKLw5QSmeCP", "uri": "/contracts/kKLw5QSmeCP#dmf", "label": "Research Collaboration and Exclusive License Agreement (Sigilon Therapeutics, Inc.)", "score": 31.8665294647, "published": true}], "snippet": "means a Drug Master File maintained with a Regulatory Authority in any country within the Territory.", "hash": "3a6ff0610710c9649d729cbafc53465c", "id": 6}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}, {"key": "the-fda", "type": "clause", "offset": [36, 43]}, {"key": "foreign-equivalent", "type": "definition", "offset": [66, 84]}], "size": 16, "samples": [{"hash": "cuD4xUZu4Ba", "uri": "/contracts/cuD4xUZu4Ba#dmf", "label": "Non Exclusive Collaboration and License Agreement (Skye Bioscience, Inc.)", "score": 37.1861724854, "published": true}, {"hash": "69ytVrN1qez", "uri": "/contracts/69ytVrN1qez#dmf", "label": "Non Exclusive Collaboration and License Agreement (Acumen Pharmaceuticals, Inc.)", "score": 32.2313499451, "published": true}, {"hash": "8ysldNl7diy", "uri": "/contracts/8ysldNl7diy#dmf", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}], "snippet": "means a Drug Master File filed with the FDA, EMA, MHLW or another foreign equivalent.", "hash": "2b7c12ccdedc02b0c0cf93ab70f0deb9", "id": 7}, {"snippet_links": [{"key": "the-united-states", "type": "definition", "offset": [19, 36]}, {"key": "social-security-administration", "type": "clause", "offset": [37, 67]}, {"key": "death-master-file", "type": "clause", "offset": [70, 87]}, {"key": "a-person", "type": "definition", "offset": [248, 256]}, {"key": "full-version", "type": "definition", "offset": [326, 338]}], "size": 13, "samples": [{"hash": "jJppFle9TJK", "uri": "/contracts/jJppFle9TJK#dmf", "label": "Global Resolution Agreement", "score": 25.9765338898, "published": true}, {"hash": "sohvKh9PvQ", "uri": "/contracts/sohvKh9PvQ#dmf", "label": "Global Resolution Agreement", "score": 24.4299221039, "published": true}, {"hash": "lhtLa4NNitb", "uri": "/contracts/lhtLa4NNitb#dmf", "label": "Global Resolution Agreement", "score": 24.4299221039, "published": true}], "snippet": "means a version of the United States Social Security Administration\u2019s Death Master File or any other database or service that is at least as comprehensive as the United States Social Security Administration\u2019s Death Master File for determining that a person has reportedly died. The Death Master File must include at least one full version of the file and may include update files.", "hash": "4ab56e8e6e79e91c86b7fabe4b5f44c7", "id": 8}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "the-us", "type": "clause", "offset": [23, 30]}, {"key": "drug-master-file", "type": "definition", "offset": [35, 51]}, {"key": "code-of-federal-regulations", "type": "definition", "offset": [106, 133]}, {"key": "supplements-and-amendments", "type": "clause", "offset": [149, 175]}, {"key": "legal-jurisdiction", "type": "definition", "offset": [210, 228]}], "size": 13, "samples": [{"hash": "j44PL5XGFzC", "uri": "/contracts/j44PL5XGFzC#dmf", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 27.0068454742, "published": true}, {"hash": "hlS0hCx7HWx", "uri": "/contracts/hlS0hCx7HWx#dmf", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 26.7494869232, "published": true}, {"hash": "lkKzWGggC3X", "uri": "/contracts/lkKzWGggC3X#dmf", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 25.3696098328, "published": true}], "snippet": "means, with respect to the U.S., a drug master file as described in Title 21, Section 314.420 of the U.S. Code of Federal Regulations, including all supplements and amendments thereto, and, with respect to any legal jurisdiction other than the U.S., analogous regulations in such legal jurisdiction.", "hash": "494c2501c2444580e6228dcf4ccec16a", "id": 9}, {"snippet_links": [{"key": "drug-master-file", "type": "definition", "offset": [8, 24]}, {"key": "in-the-united-states", "type": "clause", "offset": [37, 57]}], "size": 13, "samples": [{"hash": "inVNn1SCNIE", "uri": "/contracts/inVNn1SCNIE#dmf", "label": "Commercial Supply Agreement (Amylin Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "gjoJ9nJtK9j", "uri": "/contracts/gjoJ9nJtK9j#dmf", "label": "Commercial Supply Agreement (Amylin Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "1mLwBlGmlbQ", "uri": "/contracts/1mLwBlGmlbQ#dmf", "label": "Commercial Supply Agreement (Amylin Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet": "means a drug master file for Product in the United States (as such term is defined in 21 C.F.R. Part 314.420) or Europe.", "hash": "9b085eb3dfe73fce4f162a9b8b904d86", "id": 10}], "next_curs": "ClASSmoVc35sYXdpbnNpZGVyY29udHJhY3RzciwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIMZG1mIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "DMF", "size": 700, "snippet": "means a drug master file and all equivalents, and related proprietary dossiers, in any country or jurisdiction in the Territory (including any active substance master file in the EMA) for API submitted or to be submitted by a Party to Regulatory Authorities.", "id": "dmf", "examples": ["Halozyme shall own any <strong>DMF</strong> for the PH20 Drug substance of each Product.", "Company shall promptly notify Halozyme of any changes mandated or requested by any Regulatory Authority prior to making any such changes to the dossier or (if applicable) <strong>DMF</strong> for the PH20 Drug in order to enable the Parties to agree on the appropriate changes to be made.", "Halozyme shall promptly notify Company of any changes to the dossier or (if applicable) <strong>DMF</strong> or regulatory registration for the PH20 Drug substance.", "If Halozyme files, holds, or controls a <strong>DMF</strong> or other regulatory registration for the PH20 Drug substance: (a) Company shall have the right to cross-reference such <strong>DMF</strong> or regulatory registration; or (b) in countries where this is not feasible, Halozyme shall provide Company, at Company\u2019s cost, with such information in Halozyme\u2019s Control regarding the PH20 Drug substance of each Product as is reasonably necessary for Company to include in the applicable Regulatory Approval filings for such Product."], "related": [["master-file", "Master File", "Master File"], ["nda", "NDA", "NDA"], ["drug-master-file", "Drug Master File", "Drug Master File"], ["medicinal-product", "medicinal product", "medicinal product"], ["bla", "BLA", "BLA"]], "related_snippets": [], "updated": "2026-05-06T04:38:42+00:00"}, "json": true, "cursor": ""}}